Last updated: August 1, 2026
Duragesic-12 is the historical 12 mcg/hour transdermal fentanyl patch strength, commonly represented in current U.S. labeling as 12.5 mcg/hour. The original branded product has largely been replaced by generic fentanyl transdermal systems. No major late-stage clinical program is associated with Duragesic-12 itself. Commercial demand is declining because of opioid prescribing restrictions, safety concerns, generic substitution, and competition from non-opioid and short-acting analgesics.
What is Duragesic-12 and how does the 12 mcg/hour patch work?
Duragesic-12 delivers fentanyl continuously through the skin for approximately 72 hours. Fentanyl is a potent opioid agonist that binds primarily to mu-opioid receptors and produces analgesia, sedation, and respiratory depression.
The 12 mcg/hour strength is intended for opioid-tolerant patients who require continuous, long-term treatment for severe chronic pain. It is not an appropriate initial opioid for most patients and is not intended for acute, intermittent, postoperative, or mild pain.
| Attribute |
Duragesic-12 |
| Active ingredient |
Fentanyl |
| Delivery system |
Transdermal patch |
| Historical strength |
12 mcg/hour |
| Current common U.S. equivalent |
12.5 mcg/hour |
| Typical dosing interval |
Every 72 hours |
| Drug class |
Opioid analgesic |
| Original developer and marketer |
Janssen Pharmaceuticals |
| Current U.S. market |
Predominantly generic fentanyl patches |
| Regulatory status |
Prescription Schedule II controlled substance |
| Primary use |
Severe chronic pain in opioid-tolerant patients |
FDA labeling warns that transdermal fentanyl can cause fatal respiratory depression, accidental exposure, misuse, abuse, addiction, overdose, and death. Heat exposure can increase fentanyl absorption and raise overdose risk. [1]
What is the FDA regulatory status of Duragesic-12?
The branded Duragesic product was approved through FDA’s new drug application pathway. Generic fentanyl transdermal systems entered the market through abbreviated new drug applications, or ANDAs, demonstrating pharmaceutical equivalence and bioequivalence to the reference product.
The principal regulatory requirements are:
- Use only in opioid-tolerant patients.
- Apply the patch to intact skin.
- Replace the patch according to the labeled interval.
- Avoid external heat sources.
- Dispose of used patches securely because residual fentanyl remains in the system.
- Maintain strict controls under the Controlled Substances Act.
The 12.5 mcg/hour fentanyl patch has been retained in generic labeling, although availability varies by manufacturer, wholesaler, and pharmacy. The brand name Duragesic has substantially less commercial relevance than the active ingredient and dosage form.
What is the Orange Book status of Duragesic-12?
The commercial importance of the original Duragesic Orange Book listing is limited because the branded product is no longer the primary source of U.S. supply. Orange Book treatment of discontinued products can differ from active marketed products, and a discontinued brand does not prevent approved generic products from remaining available.
The relevant competitive issue is no longer protection of the Duragesic brand. It is the continued approval, manufacture, and supply of generic fentanyl transdermal systems.
Are there current clinical trials for Duragesic-12?
No major active clinical development program is associated with the Duragesic-12 brand. The clinical evidence base was established through earlier development of transdermal fentanyl and subsequent postmarketing experience.
Current research involving fentanyl patches is more likely to address:
- Chronic cancer pain.
- Opioid rotation.
- Pain treatment in older adults.
- Safety and misuse.
- Pharmacokinetic differences among patch products.
- Palliative-care prescribing.
- Drug disposal and accidental exposure.
These studies generally evaluate fentanyl transdermal delivery as a class rather than the Duragesic-12 brand.
What did the original Duragesic clinical program establish?
The historical development program established that transdermal fentanyl can provide continuous systemic opioid exposure over several days. The product was developed for patients requiring stable analgesia and who had already demonstrated opioid tolerance.
Clinical limitations include delayed onset, prolonged elimination after patch removal, variable absorption, and the risk that fever or external heat can raise fentanyl exposure. These characteristics limit the product’s usefulness in rapidly changing pain conditions.
Are new trials likely to expand the Duragesic-12 label?
A new label-expansion program is unlikely. The product is mature, genericized, and subject to extensive opioid safety restrictions. Potential research is more likely to support risk management, comparative safety, or specialized palliative-care use than a new commercial indication.
What patents protect Duragesic-12?
The core composition and transdermal delivery technology underlying Duragesic-12 are no longer protected by commercially meaningful basic patent exclusivity in the United States. Generic manufacturers have marketed fentanyl patches for many years.
The historical patent estate included protection relating to:
- Fentanyl delivery through a skin patch.
- Adhesive and reservoir construction.
- Rate-controlling membranes.
- Patch layering and backing materials.
- Manufacturing and packaging.
- Safety and disposal characteristics.
Most commercially relevant protection for the original product expired before the current generic market was established. Any remaining patents or regulatory exclusivities would need to be assessed against specific products, jurisdictions, and listing dates rather than the Duragesic brand generally.
How strong is the Duragesic-12 patent estate?
The estate is weak as a barrier to U.S. generic entry. The core product is mature, multiple generic manufacturers have entered, and no current patent strategy appears capable of restoring branded exclusivity for the 12 mcg/hour strength.
Potential residual barriers are operational rather than foundational:
- Technical know-how for consistent fentanyl loading.
- Adhesion performance.
- Content uniformity.
- Stability and packaging.
- Controlled-substance manufacturing permits.
- FDA inspection and compliance requirements.
- Reliable supply of fentanyl active pharmaceutical ingredient.
These factors can limit new entrants but do not provide the same protection as an unexpired composition or formulation patent.
Have generic manufacturers challenged Duragesic-12?
Generic manufacturers entered through ANDAs after the relevant reference-product exclusivities and patent barriers had expired or been resolved. Duragesic-12 is not a current high-value Paragraph IV target because the reference product is mature and the commercial opportunity is limited.
A Paragraph IV certification involves a generic applicant asserting that a listed patent is invalid, unenforceable, or not infringed. For Duragesic-12, the commercially important litigation cycle occurred years ago rather than during the current market period.
The practical generic risks now arise from:
- Additional ANDA approvals.
- Manufacturing transfers.
- Product discontinuations.
- Supply interruptions.
- State and federal opioid restrictions.
- Pharmacy substitution rules.
- Formulary changes.
What litigation and settlement agreements affect Duragesic-12?
The Duragesic franchise has been associated historically with product-liability litigation involving overdose, accidental exposure, defective warnings, adhesion, heat-related absorption, and alleged manufacturing or labeling failures. These matters are distinct from patent litigation.
Current commercial analysis should separate four categories:
| Litigation category |
Relevance to Duragesic-12 |
| Patent litigation |
Low current relevance because core protection is expired |
| Product liability |
Ongoing legal exposure across fentanyl patch products |
| Opioid marketing litigation |
Historical and industry-wide significance |
| Regulatory enforcement |
Relevant to manufacturing, distribution, labeling, and controlled-substance compliance |
Publicly reported opioid settlements generally involve broader corporate conduct and do not create new exclusivity for Duragesic-12. Settlement agreements affecting a particular patent dispute would need to be linked to a named patent, defendant, and dosage form before they could be treated as relevant to the 12 mcg/hour patch.
What formulations are protected by Duragesic-12 technology?
The original Duragesic platform used a transdermal system designed to maintain controlled fentanyl delivery. Formulation and device elements included the fentanyl-containing layer, adhesive system, backing layer, and packaging designed to protect the patch during storage.
Generic products may use different physical designs while meeting FDA requirements for pharmaceutical equivalence and bioequivalence. Device differences can affect:
- Adhesion.
- Patch handling.
- Residual drug after use.
- Skin irritation.
- Folding and disposal.
- Storage stability.
- Patient perception and adherence.
Formulation and device patents can be more relevant to an individual generic manufacturer than to the Duragesic brand as a whole. However, such patents have not prevented broad generic availability.
When does Duragesic-12 lose exclusivity?
Duragesic-12 lost practical U.S. market exclusivity years ago. The key commercial milestones were:
- Original branded approval and launch.
- Expiration or resolution of core product and delivery patents.
- Generic fentanyl patch approvals.
- Progressive substitution of generic products for Duragesic.
- Brand discontinuation or reduced distribution.
- Continued generic supply under opioid-related regulatory controls.
The product now operates in a post-exclusivity market. There is no credible commercial scenario in which the historical 12 mcg/hour Duragesic brand regains broad exclusivity without a new formulation, delivery technology, or regulatory indication.
How does Duragesic-12 compare with competing analgesics?
Duragesic-12 competes against other long-acting opioids, short-acting opioids, non-opioid analgesics, and newer drug-delivery systems.
| Product or category |
Main advantage |
Main limitation versus fentanyl patch |
| Generic fentanyl patch |
Long duration and low dosing frequency |
Delayed titration, respiratory risk, opioid tolerance required |
| Extended-release oxycodone |
Oral administration and dose flexibility |
Higher misuse concerns and frequent dosing |
| Extended-release morphine |
Low cost and broad availability |
Oral absorption variability and gastrointestinal effects |
| Buprenorphine patch |
Lower respiratory-depression ceiling than full agonists |
Different potency and indication limitations |
| Oral nonsteroidal anti-inflammatory drugs |
Non-opioid mechanism |
Gastrointestinal, renal, and cardiovascular risks |
| Acetaminophen |
Low cost and broad use |
Limited efficacy in severe chronic pain |
| Interventional pain procedures |
Can reduce systemic drug exposure |
Procedure-related cost and clinical complexity |
The closest branded competitive product is usually transdermal buprenorphine, although the products have different indications, potency, prescribing requirements, and clinical populations.
What is the market outlook for Duragesic-12?
The market outlook is negative for the original brand and stable to declining for the overall fentanyl patch category.
Demand is constrained by:
- Reduced opioid prescribing.
- CDC and state-level prescribing controls.
- Preference for non-opioid pain management.
- Safer-use restrictions in hospitals and pharmacies.
- Limited use in non-cancer chronic pain.
- Generic price competition.
- Declining willingness to initiate long-acting opioid therapy.
- Persistent concerns about diversion and accidental exposure.
Demand remains in several segments:
- Advanced cancer pain.
- Palliative care.
- Hospice.
- Patients already stabilized on transdermal fentanyl.
- Patients who cannot reliably take oral medication.
- Selected chronic pain patients under specialist supervision.
What is the 2025-2030 market projection?
The most defensible projection is a continuing decline in branded Duragesic revenue, with a slower decline in the total transdermal fentanyl market.
| Market segment |
2025-2030 outlook |
Primary driver |
| Original Duragesic brand |
Near-zero or further contraction |
Generic substitution and limited distribution |
| Generic fentanyl patches |
Low-single-digit annual decline |
Lower prescribing and price pressure |
| Cancer and palliative-care use |
Relatively stable |
Persistent need for long-term opioid delivery |
| Non-cancer chronic pain |
Moderate-to-sharp decline |
Guideline and payer restrictions |
| Total transdermal opioid category |
Decline |
Competition from buprenorphine and non-opioid treatment |
A base-case market model would assume declining unit volume, falling average selling prices, and continued concentration among a smaller number of approved manufacturers. Revenue may remain more resilient in specialist and hospice channels than in primary care.
The principal upside case is a stable cancer-pain and palliative-care segment combined with supply shortages affecting competing products. The downside case includes further prescribing restrictions, manufacturing discontinuations, or safety-driven label changes.
What manufacturing and intellectual-property barriers remain?
The main barriers are regulatory and operational rather than patent-based.
A new manufacturer must manage:
- Controlled-substance registration.
- Fentanyl API sourcing.
- Transdermal manufacturing capability.
- Adhesive and membrane performance.
- Content uniformity.
- Stability testing.
- Abuse and diversion controls.
- Child-resistant and tamper-evident packaging.
- FDA inspection requirements.
- Pharmacovigilance and product complaints.
Transdermal fentanyl products also require careful equivalence assessment. A patch is a drug-device combination product, and performance depends on both the drug formulation and physical construction. Manufacturing deviations can affect adhesion, delivery rate, or residual drug content.
Which companies are competing in the fentanyl patch market?
The U.S. market has historically included Janssen and multiple generic manufacturers. Generic availability has varied by time and channel, with manufacturers entering, exiting, or limiting distribution based on demand, compliance costs, and controlled-substance oversight.
Competition is determined less by brand differentiation than by:
- FDA approval status.
- Wholesale availability.
- Contract manufacturing.
- Supply reliability.
- Formulary placement.
- Pricing.
- Pharmacy substitution.
- Hospital and hospice contracts.
A company with an approved ANDA can still face commercial difficulty if it cannot maintain reliable supply or meet controlled-substance compliance requirements.
What revenue exposure does Duragesic-12 create for manufacturers?
Duragesic-12 has limited standalone revenue value. Public companies generally do not report the 12 mcg/hour strength separately, and historical Duragesic sales were reported within broader pain or pharmaceutical portfolios.
Revenue exposure is more relevant at the portfolio level:
- Brand owners face low direct revenue but continuing liability and compliance costs.
- Generic manufacturers face low margins and supply-chain risk.
- Distributors face controlled-substance compliance and inventory-management requirements.
- Specialty pharmacies and hospices retain recurring demand in established patients.
The product can remain strategically useful as part of a broader pain portfolio even when its direct revenue contribution is small.
What generic launch scenarios exist for Duragesic-12?
Three scenarios define the market:
Continued generic supply
Multiple suppliers maintain approval and distribution. Prices remain competitive, and the product continues to serve stable cancer and palliative-care demand.
Supplier contraction
One or more manufacturers discontinue the product, reducing availability of the 12.5 mcg/hour strength. Remaining suppliers gain temporary volume but face greater scrutiny and supply obligations.
Therapeutic substitution
Prescribers shift patients to transdermal buprenorphine, extended-release oral opioids, or non-opioid therapies. Fentanyl patch volume declines faster, especially in non-cancer chronic pain.
The most likely outcome is continued generic availability with gradual volume erosion and periodic shortages at individual pharmacies or wholesalers.
What is the geographic coverage for Duragesic-12?
Fentanyl patches remain available in multiple markets, but product names, strengths, labeling, and reimbursement differ by jurisdiction.
| Region |
Market position |
| United States |
Generic-dominated; tightly controlled opioid market |
| European Union |
Available in several countries under national brand and generic names |
| Canada |
Generic and branded transdermal fentanyl products, subject to provincial reimbursement |
| Japan |
Opioid use regulated and concentrated in specialist settings |
| Emerging markets |
Availability varies with opioid controls, affordability, and cancer-care infrastructure |
International demand is more closely linked to cancer pain treatment and palliative care than to broad chronic non-cancer pain use.
Key Takeaways
- Duragesic-12 is the historical 12 mcg/hour fentanyl patch strength, commonly labeled as 12.5 mcg/hour today.
- The original branded product has lost practical market exclusivity and has been replaced largely by generic fentanyl patches.
- No major current clinical-trial program is associated with Duragesic-12.
- Core patent protection is expired or commercially irrelevant to current generic entry.
- Current risk is concentrated in product liability, controlled-substance compliance, supply reliability, and opioid prescribing restrictions.
- The total fentanyl patch market is expected to decline gradually through 2030.
- Cancer pain, hospice, and palliative care should remain the most resilient demand segments.
- Transdermal buprenorphine, oral extended-release opioids, and non-opioid treatments are the principal competitive alternatives.
- The strongest barriers to entry are manufacturing quality, fentanyl supply, FDA compliance, and controlled-substance controls rather than patents.
Frequently Asked Questions
Is Duragesic-12 still sold under the Duragesic brand?
The original brand has limited U.S. commercial relevance. Patients generally receive a generic fentanyl transdermal system, often at the 12.5 mcg/hour strength.
Is a 12.5 mcg/hour fentanyl patch equivalent to Duragesic-12?
It is the commonly used current labeling equivalent to the historical 12 mcg/hour strength. Substitution should follow the approved product label and prescriber or pharmacist direction.
Can a new company obtain patent protection for a fentanyl patch?
A new company could pursue patents for a novel device, adhesive, formulation, manufacturing method, or delivery profile. A basic fentanyl patch patent would face substantial prior-art and obviousness challenges.
Does Duragesic-12 have biosimilar competition?
No. Biosimilar regulation applies to biologic products. Fentanyl transdermal systems are chemically synthesized drug products and compete through generic approval pathways.
What is the largest commercial risk for generic fentanyl patches?
The largest risks are declining opioid demand, controlled-substance compliance costs, supply interruptions, product-liability exposure, and pharmacy substitution pressure.
References
- U.S. Food and Drug Administration. (2023). Fentanyl transdermal system prescribing information. FDA.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.
- U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs. FDA.
- Centers for Disease Control and Prevention. (2022). CDC clinical practice guideline for prescribing opioids for pain. U.S. Department of Health and Human Services.
- National Library of Medicine. (2024). ClinicalTrials.gov. U.S. National Institutes of Health.
